10
Participants
Start Date
June 22, 2015
Primary Completion Date
June 8, 2018
Study Completion Date
June 8, 2019
BIBF 1120
Initial dose is 200 mg twice daily orally for a 28 day cycle.
Phone Call
Participant called by a member of the study staff every 3 months for up to 1 year after end-of-treatment visit. These calls should last about 2 minutes.
University of Texas MD Anderson Cancer Center, Houston
Collaborators (1)
Boehringer Ingelheim
INDUSTRY
M.D. Anderson Cancer Center
OTHER